Raltegravir
ArticlesMedicine Compliance Aid StabilityLactation Safety Information · Published , updated
429368003
Articles
23 September 2020
Safety in Lactation: HIV infection
Breastfeeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided where possible. The use of HIV drugs during breastfeeding is… Lamivudine Lopinavir + Ritonavir Raltegravir Rilpivirine Ritonavir Tenofovir Tenofovir disoproxil
17 July 2020
Switching between liquid and tablet/capsule formulations – Which medicines require extra care?
For a small number of medicines, there are differences in equivalent doses of oral formulations of the same medicine. This needs to be considered when… Alfacalcidol Captopril Carbamazepine Chloral hydrate Ciclosporin Citalopram Clobazam Cloral betaine Clozapine Co-amoxiclav Dasatinib Digoxin Emtricitabine Everolimus Fusidic acid Itraconazole Levothyroxine Lithium Lithium carbonate Lithium citrate Mebeverine Mercaptopurine Metronidazole Mycophenolate mofetil Phenytoin Phenytoin sodium Posaconazole Raltegravir Selegiline Sirolimus Sodium valproate Stiripentol Switching Tacrolimus Tenofovir Valproic acid Valsartan Vardenafil
29 March 2018
Raltegravir 600 mg once daily
Raltegravir (Isentress®) is an integrase strand transfer inhibitor licensed in combination with other antiretroviral drugs for the treatment of Human Immunodeficiency Type 1 (HIV-1) infection.… Infection and infectious diseases RaltegravirMedicine Compliance Aid Stability
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets 400mg
G1 · Green 1Stability data indicates that the drug is suitable for CAs and there are no theoretical concerns with the product.
No special precautions for storage
Manufacturer confirms stability.
5 August 2015
IsentressMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Isentress
Tablets chewable 25mg, 100mg
R1 · Red 1Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Chewable tablets stored with dessicant in original pack.
5 August 2015
Lactation Safety Information
Specialist drug/complex disease area for which expert advice is recommended
21 September 2020